Psyence Biomedical (PBM) has released an update.
Psyence Biomedical Ltd., a company developing psilocybin-based medicines, has been notified by Nasdaq of non-compliance with market value requirements, potentially leading to delisting. The firm plans to request a hearing to retain its listing while working on regaining compliance. The company’s focus is on creating psychedelic therapeutics for mental health disorders in palliative care.
For further insights into PBM stock, check out TipRanks’ Stock Analysis page.
